Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study

被引:1
作者
Wei, Yu-Ce [1 ]
Liu, Wei-Xin [2 ]
Qi, Fei [3 ]
Zhang, Chang-Gong [1 ]
Zheng, Bao-Min [2 ]
Xie, Yan [3 ]
Chen, Bo [4 ]
Zhang, Di [1 ]
Liu, Wei-Ping [3 ]
Fang, Hui [4 ]
Chai, Yue [1 ]
Qi, Shu-Nan [4 ]
Li, Ye-Xiong [4 ]
Wang, Wei-Hu [2 ]
Song, Yu-Qin [3 ]
Zhu, Jun [3 ]
Dong, Mei [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing 100142, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Radiat Oncol, Beijing, Peoples R China
关键词
Advanced-stage extranodal natural killer/T-cell lymphoma; Non-nasal type; Clinical characteristics; Prognosis; Therapeutics; NON-HODGKIN-LYMPHOMA; KI-67; EXPRESSION; SURVIVAL; SMILE; CHEMOTHERAPY; MULTICENTER; NEOPLASMS; MODEL; INDEX;
D O I
10.1007/s00277-023-05455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study aimed to investigate the clinical features, prognosis, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma (ENKTCL). This real-world study retrospectively reviewed 56 newly diagnosed advanced-stage non-nasal type ENKTCL patients from two large-scale Chinese cancer centers in the last 10-15 years and screened 139 newly diagnosed advanced-stage nasal type ENKTCLs admitted during the same period for comparison. The non-nasal type ENKTCLs exhibited significantly higher Ki-67 expression levels compared to nasal type disease (P = 0.011). With a median follow-up duration of 75.03 months, the non-nasal group showed slightly inferior survival outcomes without statistically significant differences compared to the nasal group (median overall survival (OS): 14.57 vs. 21.53 months, 5-year OS: 28.0% vs. 38.5%, P = 0.120). Eastern Cooperative Oncology Group (ECOG) score >= 2 (hazard ratio (HR) = 2.18, P = 0.039) and lactic dehydrogenase (LDH) elevation (HR = 2.44, P = 0.012) were significantly correlated with worse OS in the non-nasal group. First-line gemcitabine-based chemotherapy regimens showed a trend toward slightly improved efficacy and survival outcomes compared to non-gemcitabine-based ones in the present cohort of non-nasal ENKTCLs (objective response rate: 91.7% vs. 63.6%, P = 0.144; complete response rate: 50.0% vs. 33.3%, P = 0.502; median progression-free survival: 10.43 vs. 3.40 months, P = 0.106; median OS: 25.13 vs. 9.30 months, P = 0.125), which requires further validation in larger sample size studies. Advanced-stage non-nasal type patients could achieve comparable prognosis with nasal cases after rational therapy. The modified nomogram-revised index (including age, ECOG score, and LDH) and modified international prognostic index (including age, ECOG score, LDH, and number of extranodal involvement) functioned effectively for prognostic stratification in non-nasal type ENKTCLs.
引用
收藏
页码:163 / 174
页数:12
相关论文
共 50 条
  • [31] Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type
    Q Cai
    X Luo
    Y Liang
    H Rao
    X Fang
    W Jiang
    T Lin
    T Lin
    H Huang
    British Journal of Cancer, 2013, 108 : 380 - 386
  • [32] Diagnosis and treatment of a patient with primary gastric extranodal natural killer/T-cell lymphoma, nasal type
    Yang, Haiyan
    Wu, Meijuan
    Yin, Wenjuan
    Sun, Wenyong
    Zhang, Gu
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2137 - 2140
  • [33] Clinicopathologic and molecular features in cutaneous extranodal natural killer-/T-cell lymphoma, nasal type, with aggressive and indolent course
    Fried, Isabella
    Artl, Monika
    Cota, Carlo
    Mueller, Hansgeorg
    Bartolo, Elvira
    Boi, Sebastiana
    Chiarelli, Concetta
    Vale, Esmeralda
    Schmuth, Matthias
    Wiesner, Thomas
    Speicher, Michael R.
    Cerroni, Lorenzo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (04) : 716 - 723
  • [34] Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma
    Luo, Jialin
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Zhang, Na
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6147 - 6150
  • [35] Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type
    Cho, Hyun-Jin
    Jang, Min-Seok
    Hong, Sang Duk
    Kim, Seok Jin
    Ahn, Yong Chan
    Oh, Dongryul
    Ko, Young Hyeh
    Kim, Hyo Yeol
    Dhong, Hun-Jong
    Chung, Seung-Kyu
    Kim, Won Seog
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2015, 5 (10) : 960 - 966
  • [36] CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
    Li, Pengfei
    Jiang, Li
    Zhang, Xinke
    Liu, Jun
    Wang, Hua
    BMC CANCER, 2014, 14
  • [37] Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
    Kim, Seok Jin
    Jung, Hyun Ae
    Chuang, Shih-Sung
    Hong, Huangming
    Guo, Cheng-Cheng
    Cao, Junning
    Hong, Xiao-Nan
    Suzuki, Ritsuro
    Kang, Hye Jin
    Won, Jong Ho
    Chng, Wee-Joo
    Kwong, Yok-Lam
    Suh, Cheolwon
    Song, Yu-Qin
    Zhu, Jun
    Tay, Kevin
    Lim, Soon Thye
    Suzumiya, Junji
    Lin, Tong-Yu
    Kim, Won Seog
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [38] CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
    Pengfei Li
    Li Jiang
    Xinke Zhang
    Jun Liu
    Hua Wang
    BMC Cancer, 14
  • [39] New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning
    Sun, Jianbin
    Ke, Xiaoyan
    Zhang, Mingzhi
    Wang, Yuhui
    An, Fengyang
    Zhao, Yulin
    Zhu, Li
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (02) : 613 - 626
  • [40] Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database
    Liu, Xin
    Zhang, Li-Ling
    Qu, Bao-Lin
    Zhong, Qiu-Zi
    Qian, Li-Ting
    Yang, Yong
    Hou, Xiao-Rong
    Qiao, Xue-Ying
    Wang, Hua
    Zhu, Yuan
    Cao, Jian-Zhong
    Wu, Jun-Xin
    Wu, Tao
    Zhu, Su-Yu
    Shi, Mei
    Zhang, Hui-Lai
    Zhang, Xi-Mei
    Su, Hang
    Song, Yu-Qin
    Zhu, Jun
    Zhang, Yu-Jing
    Huang, Hui-Qiang
    Wang, Ying
    Chen, Fan
    Yin, Lin
    He, Xia
    Cai, Shang
    Li, Ye-Xiong
    Qi, Shu-Nan
    HAEMATOLOGICA, 2023, 108 (09) : 2467 - 2475